A study evaluating the safety and efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemia

Update Il y a 5 ans
Reference: EUCTR2015-003909-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to determine the preliminary efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with relapsed or refractory CLL


Inclusion criteria

  • Adults with relapsed or refractory chronic lymphocytic leukemia (CLL)

Links